=> b caplus COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:34:01 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2008 VOL 149 ISS 1 FILE LAST UPDATED: 29 Jun 2008 (20080629/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 87-89-8/biol,anst,ract 9934 87-89-8 7409415 BIOL/RL 6384 87-89-8/BIOL (87-89-8 (L) BIOL/RL)9934 87-89-8 1213403 ANST/RL 845 87-89-8/ANST (87-89-8 (L) ANST/RL)9934 87-89-8 3125884 RACT/RL 461 87-89-8/RACT (87-89-8 (L) RACT/RL)T.1 7412 87-89-8/BIOL, ANST, RACT => s 60-27-5/biol, anst, ract21108 60-27-5 7409415 BIOL/RL 15715 60-27-5/BIOL (60-27-5 (L) BIOL/RL)21108 60-27-5 1213403 ANST/RL 3169 60-27-5/ANST

> 21108 60-27-5 3125884 RACT/RL

> > 216 60-27-5/RACT

(60-27-5 (L) ANST/RL)

```
(60-27-5 (L) RACT/RL)
         18293 60-27-5/BIOL, ANST, RACT
L2
=> s L1 and L2
           87 L1 AND L2
T.3
=> s L3 and urine
        227568 URINE
          4799 URINES
        228046 URINE
                 (URINE OR URINES)
            20 L3 AND URINE
T.4
=> s L4 and (glucose or insulin or diabet##)
        451491 GLUCOSE
           878 GLUCOSES
        451689 GLUCOSE
                 (GLUCOSE OR GLUCOSES)
        222481 INSULIN
          5351 INSULINS
        222563 INSULIN
                 (INSULIN OR INSULINS)
        160285 DIABET##
L5
            16 L4 AND (GLUCOSE OR INSULIN OR DIABET##)
=> s L5 and py>2003
       5919684 PY>2003
L6
             8 L5 AND PY>2003
=> s L5 and py<2003
      22935492 PY<2003
             8 L5 AND PY<2003
T.7
=> d L7 ibib abs 1-8
     ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
L.7
ACCESSION NUMBER:
                         2002:463958 CAPLUS <<LOGINID::20080630>>
DOCUMENT NUMBER:
                         138:22988
TITLE:
                         Correlation between urinary excretion of polyol
                         products and type IV collagen in Japanese type 1
                         diabetic patients
AUTHOR(S):
                         Takaike, Hiroko; Miura, Junnosuke; Ohsawa, Mari;
                         Uchigata, Yasuko; Iwamoto, Yasuhiko
                         Diabetes Center, Tokyo Women's Medical University
CORPORATE SOURCE:
                         School of Medicine, Tokyo, Japan
SOURCE:
                         Tonyobyo (Tokyo, Japan) (2002), 45(3),
                         173-180
                         CODEN: TONYA4; ISSN: 0021-437X
                         Nippon Tonyobyo Gakkai
PUBLISHER:
DOCUMENT TYPE:
                         Journal
LANGUAGE:
                         Japanese
     Poor glycemic control greatly influences the development of
AB
     diabetic complications, and acceleration of the polyol pathway is
     one of the main factors causing microangiopathy. We clarified whether the
     urinary excretion of polyol products was related to clin. severity of
     diabetic complications in 153 type 1 diabetic patients
     whose urinary albumin creatinine ratio (ACR) was under 100 mg/g Cr. Optic
     fundi were checked by ophthalmologists and ACR, type IV collagen
     creatinine ratio (U-IV-C), and urinary polyol products such as sorbitol,
     fructose, and myo-inositol were measured by using a single-void first
     morning urine. Patients with retinopathy excrete more fructose
```

and myo-inositol greater than those without retinopathy. ACR showed no relationship with urinary polyol products. Urinary type IV collagen independently showed a pos. correlation to urinary myo-inositol. Production of type IV collagen was accelerated by high glucose, indicating expansion of the mesangium. Increased urinary myo-inositol may reflect activation of the polyol pathway in the diabetic kidney. Measurement of both urinary myo-inositol and U-IV-C is important in ascertaining the existence of renal impairment caused by high glucose.

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:514788 CAPLUS <<LOGINID::20080630>>

DOCUMENT NUMBER: 135:89514

TITLE: Enzymic method for diagnosing pre-diabetes

group

INVENTOR(S): Takatsuma, Takashi; Takahashi, Mamoru PATENT ASSIGNEE(S): Asahi Chemical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001190299 JP 3975279	A B2	20010717 20070912	JP 2000-335277	20001101 <

PRIORITY APPLN. INFO.: JP 1999-311482 A 19991101

AB A convenient and accurate enzymic method is provided for distinguishing diabetes patients including pre-diabetes group from non-diabetes patients using samples collected from patients. A sample

(e.g., urine) is treated with a myoinositol-degrading enzyme without pretreatment, and myoinositol contained in the sample is degraded.

The myoinositol content in the sample is determined by measuring the degradation

product. Depending upon the determined value, a distinction is made among normal persons, pre-diabetes group patients (boundary type,

impaired glucose tolerance, impaired fasting glycemia,

insulin resistance) and diabetes patients.  $\ensuremath{\mathtt{A}}$ 

dehydrogenase (e.g., inositol dehydrogenase from Klebsiella, Bacillus sp., Flavobacterium), a kinase (e.g., inositol kinase), an oxidase (e.g., inositol oxygenase, pyranose oxidase) or else is used as an enzyme.

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:579320 CAPLUS <<LOGINID::20080630>>

DOCUMENT NUMBER: 133:279942

TITLE: Aldose reductase-deficient mice develop nephrogenic

diabetes insipidus

AUTHOR(S): Ho, Horace T. B.; Chung, Sookja K.; Law, Janice W. S.;

Ko, Ben C. B.; Tam, Sidney C. F.; Brooks, Heddwen L.;

Knepper, Mark A.; Chung, Stephen S. M.

CORPORATE SOURCE: Institute of Molecular Biology, The University of Hong

Kong, Hong Kong, Peop. Rep. China

SOURCE: Molecular and Cellular Biology (2000),

20(16), 5840-5846

CODEN: MCEBD4; ISSN: 0270-7306 American Society for Microbiology

DOCUMENT TYPE: Journal LANGUAGE: English

PUBLISHER:

AB Aldose reductase (ALR2) is thought to be involved in the pathogenesis of

various diseases associated with diabetes mellitus, such as cataract, retinopathy, neuropathy, and nephropathy. However, its physiol. functions are not well understood. We developed mice deficient in this enzyme and found that they had no apparent developmental or reproductive abnormality except that they drank and urinated significantly more than their wild-type littermates. These ALR2-deficient mice exhibited a partially defective urine-concentrating ability, having a phenotype resembling that of nephrogenic diabetes insipidus.

39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:207348 CAPLUS <<LOGINID::20080630>>

130:234331 DOCUMENT NUMBER:

TITLE: Chemical diagnosis based on urine

metabolites measured by GC/MS

Matsumoto, Isamu; Chou, Shunka INVENTOR(S):

Mills Seimei Kagaku Kenkyujo K. K., Japan Jpn. Kokai Tokkyo Koho, 10 pp. PATENT ASSIGNEE(S):

SOURCE:

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11083860	A	19990326	JP 1997-245252	19970910 <
JP 3129250	B2	20010129		

PRIORITY APPLN. INFO.: JP 1997-245252

The diagnosis is performed by (1) treating samples, e.g. urine components extracted from urine-impregnated filter papers, with urease, (2) adding internal stds. to the samples, (3) trimethylsilylating the metabolites including creatinine (I) for GC/MS, (4) multiplying the measured values of I by a correction coefficient for I calculated by any other anal. method such as Jaffe method, (5) displaying the contents of the other metabolites as the measured values to the corrected I value, (6) inputting the measured values to a calculator for comparing those values with normal values, and (7) displaying abnormal values and findings corresponding the abnormal values the method eliminates the need for parallel analyses for I by GC/MS anal. and chemical anal.finding list. The method eliminates the need for parallel analyses for I by GC/MS anal. and chemical anal. The method is useful for diagnosis of metabolic disorders, e.g. diabetes, gout, etc.

ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:140990 CAPLUS <<LOGINID::20080630>> DOCUMENT NUMBER: 126:141757

ORIGINAL REFERENCE NO.: 126:27323a,27326a

Method of optically measuring a component in solution TITLE:

INVENTOR(S): Wang, Yung Xiang; Dou, Xiaoming
PATENT ASSIGNEE(S): Kyoto Dai-Ichi Kagaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 58 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE PATENT NO.

EP 751388	A2	19970102	EP 1996-110521		19960628 <
EP 751388	A3	19970507			
EP 751388	B1	20020911			
R: DE, FR, GB,	ΙT				
JP 09015155	A	19970117	JP 1995-186341		19950628 <
JP 09079982	A	19970328	JP 1995-262338		19950913 <
US 5796476	A	19980818	US 1996-672026		19960626 <
CN 1157919	A	19970827	CN 1996-108652		19960628 <
CN 1114098	В	20030709			
PRIORITY APPLN. INFO.:			JP 1995-186341	Α	19950628
			JP 1995-262338	Α	19950913

A sample solution containing protein is irradiated with excitation light of a single wavelength which is emitted from a light source so that light scattered from the sample solution is received and separated into its spectral components in a spectroscope, thereby obtaining light scattering spectra. Protein is quant. measured through intensity of a light scattering spectrum in a shift wavenumber of 100-3100 cm-1 with respect to the excitation wavelength among the light scattering spectra or an integral value in a proper range therein. As to a body fluid sample (e.g., urine, blood, blood plasma, blood serum, saliva, or sweat), the sample is irradiated with excitation light, and Raman scattering spectral intensity values are measured at a plurality of wavenumbers in an arbitrary wavenumber range, and a plurality of components in the sample are analyzed simultaneously by multivariate regression anal.

ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:160276 CAPLUS <<LOGINID::20080630>>

DOCUMENT NUMBER: 114:160276

ORIGINAL REFERENCE NO.: 114:27007a,27010a

TITLE: Automated screening of urine samples for

carbohydrates, organic and amino acids after treatment

with urease

Shoemaker, James D.; Elliott, William H. AUTHOR(S):

CORPORATE SOURCE: Med. Cent., Saint Louis Univ., St. Louis, MO, 63104,

USA

SOURCE: Journal of Chromatography (1991), 562(1-2),

125-38

CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal LANGUAGE: English

Eighty-five clin. urine samples and nineteen urine samples previously found by other labs. to suggest genetic metabolic defects were prepared for trimethylsilylation by treatment with urease, followed by azeotropic dehydration. The Target Analyte Search program provided with the VG Trio 2 gas chromatograph-mass spectrometer required 6 min to quantify 103 compds. relative to endogenous urinary creatinine. This technique has been used to confirm diagnoses including cystinuria, lysinuria, medium-chain acyldehydrogenase deficiency, ornithine transcarbamylase deficiency, aspartylglucosaminuria, methylmalonic, propionic and glutaric acidurias.

ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:20351 CAPLUS <<LOGINID::20080630>>

DOCUMENT NUMBER: 114:20351

ORIGINAL REFERENCE NO.: 114:3573a,3576a

TITLE: Urinary polyol profiles in patients with chronic liver

diseases and their correlation with severity, as

obtained by capillary gas chromatography

AUTHOR(S): Haga, Hidehiko; Horie, Yukio; Ikeda, Hitoshi; Oka,

Hiroshi; Nakajima, Terumi

CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan SOURCE: Analytical Sciences (1990), 6(5), 667-70

CODEN: ANSCEN; ISSN: 0910-6340

DOCUMENT TYPE: Journal LANGUAGE: English

AB A capillary gas chromatog. method for urinary polyol profiling anal. was applied to a study of urinary polyols in patients with chronic liver diseases. There was no statistically significant difference in any urinary polyols between the groups with and without glucose infusion. Ribitol, xylitol, and sorbitol in patients significantly increased, and arabitol significantly decreased compared with the amts. from normal subjects. It is striking that the decrease of arabitol and the increased abnormal incidence of mannitol and sorbitol were well correlated with the severity of chronic liver diseases according to the Child-Turcott Classification. Urinary polyol profiling anal. may be useful in assessment of hepatic functional reserve.

L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:20350 CAPLUS <<LOGINID::20080630>>

DOCUMENT NUMBER: 114:20350

ORIGINAL REFERENCE NO.: 114:3573a,3576a

TITLE: Diagnostic profiling analysis of polyols in

urine samples of patients with various

diseases performed by capillary gas chromatography AUTHOR(S): Haga, Hidehiko; Kamei, Sachiko; Ohkubo, Akiyuki;

Nakajima, Terumi

CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan

SOURCE: Analytical Sciences (1990), 6(5), 657-66

CODEN: ANSCEN; ISSN: 0910-6340

DOCUMENT TYPE: Journal LANGUAGE: English

AB A capillary gas chromatog. method, based on trifluoroacetylated polyols, was applied to a study of urinary polyols in normal subjects and in patients with various diseases. Polyol excretion patterns during fasting periods and circadian variants were studied in normal subjects. Twenty-four h urine sample sets of normal subjects showed almost constant polyol profiles, suggesting the existence of a polyol regulation system in the body. Excretion patterns of 10 polyols were studied in 100 specimens of 24-h urine samples from patients hospitalized with various diseases. Polyol profiles showed patterns characteristic of pathol. states of the diseases: such as diabetes mellitus, chronic renal failure, and chronic liver diseases. The possibility of diagnosis of several diseases by urinary polyol profiles is presented.